



# Total synthesis of the marine pyrroloiminoquinone alkaloid tsitsikammamine A

Arnaud Rives, Tamara Delaine, Laurent Legentil, Evelyne Delfourne \*

Université Paul Sabatier, UMR CNRS 5068, Laboratoire de Synthèse et Physicochimie de Molécules d'Intérêt Biologique, 118 route de Narbonne, 31062 Toulouse Cédex 9, France

## ARTICLE INFO

### Article history:

Received 24 October 2008

Revised 15 December 2008

Accepted 16 December 2008

Available online 24 December 2008

### Keywords:

Synthesis

Marine alkaloid

Pyrroloiminoquinone

Tsitsikammamine


## ABSTRACT

A concise route to the marine pyrroloiminoquinone alkaloid tsitsikammamine A and a regioisomer was developed. The synthesis was based on a Michael reaction between the indole dione **6** and 2'-amino-1-(4-methoxyphenyl)ethanol.

© 2008 Elsevier Ltd. All rights reserved.

Marine organisms provide a valuable source for natural products. In the past several years, many new pyrroloiminoquinone alkaloids have been isolated mainly from sponges.<sup>1</sup> This class of compounds consisting of prianosins, discorhabdins, batzellins, wakayin, damirone, and makaluvamines possesses a pyrrolo[4,3,2-*de*]quinoline skeleton. Due to their remarkable biological activities, a number of synthetic methodologies have been developed to prepare the natural products<sup>2</sup> and analogues.<sup>3</sup>

Tsitsikammamines A (**1**) and B (**2**)<sup>4</sup>, two alkaloids closely structurally related to wakayin **3**<sup>5</sup> and isolated from a *Latrunculid* sponge, have been reported to exhibit cytotoxicity and topoisomerase I inhibition.




- 1, R<sub>1</sub> = R<sub>2</sub> = H  
 2, R<sub>1</sub> = Me, R<sub>2</sub> = H  
 4, R<sub>1</sub> = H, R<sub>2</sub> = OH  
 5, R<sub>1</sub> = Me, R<sub>2</sub> = OH

Recently, reinvestigation of extracts of the same sponge searching for minor pyrroloiminoquinone metabolites yielded N-18 oxime analogues of tsitsikammamine A and B, **4** and **5**, respectively. These compounds exhibited significantly reduced cytotoxicity

\* Corresponding author. Tel.: +33 561 55 62 93; fax: +33 561 55 60 11.  
 E-mail address: [delfourn@chimie.ups-tlse.fr](mailto:delfourn@chimie.ups-tlse.fr) (E. Delfourne).


ity against human colon tumor (HCT-116) when compared with their parent alkaloids.<sup>6</sup> Despite different works by our group<sup>7</sup> and by others<sup>8</sup> to propose analogues of wakayin and tsitsikammamines with potential antitumor activity, and thought that these alkaloids have been isolated for quite a while now, no synthesis of these marine metabolites has been reported to date. We describe herein the first total synthesis of tsitsikammamine A and one of its regioisomers.

The initial retrosynthetic pathway investigated was based on a Michael addition between the previously described indole dione **6**<sup>7b</sup> and 4'-methoxy-2-aminoacetophenone **7**.



This last β-ketoamine was synthesized in one step according to Grayson and Heyes' method<sup>9</sup> involving anisole which was reacted with gaseous HCl in the presence of AlCl<sub>3</sub>. Compound **7** was obtained as a hydrochloride salt in 50% yield. The coupling reaction of this salt with compound **6** did not give the expected adduct **8a** whatever the experimental conditions used, but afforded mainly (41% yield) one of regioisomers **9a** or **9b**. It is noteworthy that the same reaction was observed when the methoxyphenyl group was

replaced by a phenyl group (77% yield) or by an indole group (58% yield).




An alternative route to prepare intermediate **8** relied on the reduction of the carbonyl function of **7** prior to the Michael addition. This reduction effected by NaBH<sub>4</sub> provided β-hydroxyamine **10** in 72% yield. Reaction of **10** with quinone **6** in absolute ethanol gave two regioisomers **11a** and **11b** (57% and 19%, respectively, **a** and **b** refer to the order of elution during the purification by silica gel flash chromatography). Dess–Martin periodinane oxidation of these alcohols provided the two corresponding β-keto-adducts **8a** and **8b**.<sup>10</sup> Attempts to cyclize these products failed.

Surprisingly, the formation of the second five-membered nitrogen ring was achieved by direct cyclization of the hydroxy-derivatives **11a** and **11b** in trifluoroacetic acid and CH<sub>2</sub>Cl<sub>2</sub>, and was concomitant with the cleavage of the Boc protective group leading to compounds **12a** and **12b**.

MnO<sub>2</sub> oxidation of these compounds gave the bispyrroloquinone derivatives **13a** and **13b** which were subsequently cyclized into the corresponding iminoquinones **14a** and **14b**. The overall yields of these three steps were 16% and 22%, respectively. It has to be noted that few amounts (<4%) of compounds **14a** and **14b** were also formed during the cyclization step involving trifluoroacetic acid when the reaction was conducted in the absence of solvent. The tosyl group of **14a** and **14b** was removed by action of 1 N NaOH in dioxane leading to compounds **15a** and **15b** (46% and 40% yield, respectively), together with secondary compounds **16a** and **16b**. The free base of tsitsikammamine A **17b** was readily obtained by demethylation of compound **15b** using BBr<sub>3</sub>, whereas the same reaction conditions applied on compound **15a** afforded the non-natural regioisomer **17a**.<sup>11</sup>

The spectroscopic data of the trifluoroacetic salt of **17b** were shown to be identical with those reported for tsitsikammamine A (**1**).<sup>4</sup> Investigations are currently in progress to apply this synthetic route to the other marine metabolite wakayin **3**.



a- abs EtOH, rt, 2h. b- TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 4h. c- MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight. d- abs EtOH, 4Å molecular sieve, reflux, 3h. e- 1N NaOH, dioxane, rt, overnight. f- BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, N<sub>2</sub>, 4h.

## References and notes

- (a) Ding, Q.; Chichak, K.; Lown, J. W. *Curr. Med. Chem.* **1999**, *6*, 1–27; (b) Urban, S.; Hickford, S. J. H.; Blunt, J. W.; Munro, M. H. G. *Curr. Org. Chem.* **2000**, *4*, 765–778; (c) Antunes, E. M.; Copp, B. R.; Davies-Coleman, M. T.; Samaai, T. *Nat. Prod. Rep.* **2005**, *22*, 62–72.
- Harayama, Y.; Kita, Y. *Curr. Org. Chem.* **2005**, *9*, 1567–1588.
- (a) Delfourne E. *Anti-Cancer Agents Med. Chem.*, in press.; (b) Shinkre, B. A.; Raisch, K. P.; Fan, L.; Velu, S. E. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 2890–2893; (c) Shinkre, B. A.; Raisch, K. P.; Fan, L.; Velu, S. E. *Bioorg. Med. Chem.* **2008**, *16*, 2541–2549; (d) Passarella, D.; Belinghieri, F.; Scarpellini, M.; Pratesi, G.; Zunino, F.; Gia, O. M.; Via, L. D.; Santoro, G.; Danieli, B. *Bioorg. Med. Chem.* **2008**, *16*, 2431–2438.
- Hooper, G. J.; Davies-Coleman, M. T.; Kelly-Borges, M.; Coetzee, P. S. *Tetrahedron Lett.* **1996**, *37*, 7135–7138.
- Copp, B. R.; Ireland, C. M.; Barrows, L. R. *J. Org. Chem.* **1991**, *56*, 4596–4597.
- Antunes, E. M.; Beukes, D. R.; Kelly, M.; Samaai, T.; Barrows, L. R.; Marshall, K. M.; Sincich, C.; Davies-Coleman, M. T. *J. Nat. Prod.* **2004**, *67*, 1268–1276.
- (a) Legentil, L.; Lesur, B.; Delfourne, E. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 427–429; (b) Legentil, L.; Benel, L.; Bertrand, V.; Lesur, B.; Delfourne, E. *J. Med. Chem.* **2006**, *49*, 2979–2988.
- (a) Zhang, L.; Cava, M. P.; Rogers, R. D.; Rogers, L. M. *Tetrahedron Lett.* **1998**, *39*, 7677–7678; (b) Barret, R.; Roue, N. *Tetrahedron Lett.* **1999**, *40*, 3889–3890; (c) LaBarbera, D. V.; Skibo, E. B. *Bioorg. Med. Chem.* **2005**, *13*, 387–395; (d) Hoang, H.; LaBarbera, D. V.; Mohammed, K. A.; Ireland, C. M.; Skibo, E. B. *J. Med. Chem.* **2007**, *50*, 4561–4571; (e) Hoang, H.; Huang, X.; Skibo, E. B. *Org. Biomol. Chem.* **2008**, *6*, 3059–3064.
- Grayson, J. I.; Heyes, G. EP 0 431 871 A2, 1990.
- Dess, D. B.; Martin, J. C. *J. Am. Chem. Soc.* **1991**, *113*, 7277–7287.
- Tsitsikammamine A (free base, 17b)** HRMS (ESI) calcd for C<sub>18</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub> 304.1086 (MH<sup>+</sup>), found 304.1130. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) 2.71 (t, 2H, *J* = 7.8 Hz), 3.97 (t, 2H, *J* = 7.8 Hz), 6.74 (d, 2H, *J* = 8.4 Hz), 6.96 (d, 1H, *J* = 2.1 Hz), 7.16 (d, 1H, *J* = 3.0 Hz), 7.68 (d, 2H, *J* = 8.4 Hz), 9.37 (br s, 1H), 12.15 (br s, 1H), 12.44 (br s, 1H). <sup>13</sup>C (DMSO-*d*<sub>6</sub>) 18.35, 49.07, 115.07 (3C), 118.13, 121.84, 122.18, 122.52, 123.51, 125.27, 125.49, 130.16 (2C), 133.83, 154.96, 156.71, 167.99. **(17a)** HRMS (ESI) calcd for C<sub>18</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub> 304.1086 (MH<sup>+</sup>), found 304.1064. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) 2.73 (t, 2H, *J* = 8.1 Hz), 4.05 (t, 2H, *J* = 8.1 Hz), 6.72 (d, 2H, *J* = 8.7 Hz), 6.82 (s, 1H), 6.95 (s, 1H), 7.47 (d, 2H, *J* = 8.7 Hz), 7.60 (br s, 1H), 7.70 (br s, 1H), 11.81 (br s, 1H). <sup>13</sup>C (DMSO-*d*<sub>6</sub>) 18.92, 49.05, 11.83 (2C), 115.04, 116.13, 119.85, 120.66, 120.93, 125.57, 126.41, 129.46, 130.36 (2C), 134.26, 150.57, 156.58, 174.49.